MDR-1339

Research use only, not for human use.

MDR-1339 is a blood-brain-barrier-permeable inhibitor of amyloid-β (Aβ) aggregation.

MDR-1339 is a blood-brain-barrier-permeable inhibitor of amyloid-β (Aβ) aggregation.(In Vitro):MDR-1339 (1.5-10 μM) protects cells from this Aβ-induced toxicity. MDR-1339 (3.1-50 μM) also blocks the formation of Aβ aggregates and disaggregates Aβ fibrils in a dose-dependent manner.(In Vivo):In APP/PS1 mice, MDR-1339 (30 and 100 mg/kg, p.o.) significantly improves spontaneous alternation and reduces the Aβ1-40 and Aβ1-42 levels. MDR-1339 (0.1-10 mg/kg, p.o.) restores the passive avoidance responses in mice models of Alzheimer's disease (ED50 = 0.19 mg/kg) in a dose-dependent manner.

MDR-1339 is an Aβ-aggregation inhibitor, and shows no significant inhibition a panel of CYP isozymes, while it slightly inhibits CYP2C8 (IC50, 31.4 μM). MDR-1339 (3.1-50 μM) dose-dependently blocks the formation of Aβ aggregates, and disaggregates Aβ fibrils. MDR-1339 (1.5-10 μM) also protects cells from this Aβ-induced toxicity.

MDR-1339 (0.1-10 mg/kg, p.o.) dose-dependently restores the passive avoidance responses in mice models of Alzheimer's disease (AD), with an ED50 of 0.19 mg/kg. MDR-1339 (30 and 100 mg/kg, p.o. daily for 8 weeks) significantly improves spontaneous alternation, and reduces the Aβ1-40 and Aβ1-42 levels in APP/PS1 mice.

DWK-1339

Membrane Transporter/Ion Channel

Beta Amyloid

Beta Amyloid

——

——

1018946-38-7

326.392

C20H22O4

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (153.19 mM)

COCCCc1ccc2oc(cc2c1)-c1ccc(OC)c(OC)c1

——

(-20℃)

With Ice Pack

≥ 2 years